Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Tuesday reported a loss of $29.1 million in its fourth quarter. The San Diego-based company said it had a loss of $1.03 per share. The ...
Management is transitioning the ARCT-032 cystic fibrosis program into a 12-week Phase II study to better capture clinical healing and efficacy signals beyond the initial 'onboarding' phase. The ...
About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Hosted on MSN
Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results